These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38513637)
1. A pledge for a better care and consideration of patients with vitiligo. Passeron T Br J Dermatol; 2024 Apr; 190(5):614-615. PubMed ID: 38513637 [No Abstract] [Full Text] [Related]
2. Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score. Fakih A; Tannous R; Lajnef M; Seneschal J; Andreu N; Tran VT; Ezzedine K Br J Dermatol; 2024 Apr; 190(5):712-717. PubMed ID: 38234050 [TBL] [Abstract][Full Text] [Related]
10. A measurement of the stigma among vitiligo and psoriasis patients in India. Pichaimuthu R; Ramaswamy P; Bikash K; Joseph R Indian J Dermatol Venereol Leprol; 2011; 77(3):300-6. PubMed ID: 21508568 [TBL] [Abstract][Full Text] [Related]
11. Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021. Learned C; Cohen SR; Alsukait S; Deverapalli S; Rosmarin D J Am Acad Dermatol; 2023 Jan; 88(1):197-199. PubMed ID: 35427685 [No Abstract] [Full Text] [Related]
12. Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo. Merhi R; Canu D; Barnetche T; Duchez E; Gey A; Andreu N; Taieb A; Boniface K; Seneschal J Br J Dermatol; 2022 Sep; 187(3):422-424. PubMed ID: 35289925 [No Abstract] [Full Text] [Related]
13. Quality of Life Impairment in Children and Adults with Vitiligo: A Cross-Sectional Study Based on Dermatology-Specific and Disease-Specific Quality of Life Instruments. Catucci Boza J; Giongo N; Machado P; Horn R; Fabbrin A; Cestari T Dermatology; 2016; 232(5):619-625. PubMed ID: 27603174 [TBL] [Abstract][Full Text] [Related]
14. Vitiligo-like manifestations of graft-versus-host disease in a pediatric population. Dai J; Hight RS; Grullon K; Xiao TL; Stein SL Pediatr Dermatol; 2023 Jan; 40(1):157-161. PubMed ID: 36063124 [TBL] [Abstract][Full Text] [Related]
15. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Merimsky O; Shoenfeld Y; Yecheskel G; Chaitchik S; Azizi E; Fishman P Cancer Immunol Immunother; 1994 Jun; 38(6):411-6. PubMed ID: 8205563 [TBL] [Abstract][Full Text] [Related]
16. Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo. Fukuda K; Harris JE J Am Acad Dermatol; 2018 Jan; 78(1):e15-e16. PubMed ID: 29241799 [No Abstract] [Full Text] [Related]
17. Vitiligo Impact Scale (VIS)-22: A measure of the psycho-social burden of vitiligo. Gupta V; Ramam M Indian J Dermatol Venereol Leprol; 2022; 88(5):691-695. PubMed ID: 35962518 [No Abstract] [Full Text] [Related]
18. Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. Boniface K; Dutriaux C; Prey S; Taieb A; Seneschal J J Am Acad Dermatol; 2018 Jan; 78(1):e17-e18. PubMed ID: 29241800 [No Abstract] [Full Text] [Related]
19. Practice and Educational Gaps in Abnormal Pigmentation. Mohammad TF; Hamzavi IH Dermatol Clin; 2016 Jul; 34(3):291-301. PubMed ID: 27363886 [TBL] [Abstract][Full Text] [Related]
20. Application of a pigment measuring device--Mexameter--for the differential diagnosis of vitiligo and nevus depigmentosus. Park ES; Na JI; Kim SO; Huh CH; Youn SW; Park KC Skin Res Technol; 2006 Nov; 12(4):298-302. PubMed ID: 17026663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]